Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 288 for infectious diseases

Edit search filters
  1. Expanded Access Use of Brincidofovir for BK Polyomavirus

    Rochester, MN

  2. A Study to Evaluate NPC-21 to Treat Kidney Transplant Patients at High Risk for Cytomegalorvirus Infection

    Scottsdale/Phoenix, AZ

  3. Study to Evaluate the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection

    Rochester, MN

  4. A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1

    Rochester, MN

  5. Study Using Clofazimine to Treat Patients with Non-Tuberculous Mycobacterial Infections

    Scottsdale/Phoenix, AZ

  6. Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

    Rochester, MN

  7. Treatment of Recurrent Clostridium Difficile Infection with RBX7455

    Rochester, MN

  8. An Extension of a Previous Study Evaluating the Use of SER-109 to Prevent Recurrent Clostridium Difficile Infections

    Rochester, MN

  9. Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

    Scottsdale/Phoenix, AZ

  10. A Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection

    Rochester, MN

.

Mayo Clinic Footer